Meeting of the National Vaccine Advisory Committee, 56427-56428 [2022-19849]

Download as PDF Federal Register / Vol. 87, No. 177 / Wednesday, September 14, 2022 / Notices Organizations selected by OWH to be Women’s Health Champions will sign a letter of understanding (LOU) with OWH outlining the terms and parameters of their support for the observance(s). Selection as a Women’s Health Champion does not imply any federal endorsement of the collaborating organization’s general policies, activities, or products. Eligibility for Interested Organizations: To be eligible to become a Women’s Health Champion, an organization shall: (1) Have a demonstrated interest in, understanding of, and experience promoting access to resources and information regarding the observance’s goals; or (2) have an organizational or corporate mission that is aligned with the observance’s goals; and (3) agree to sign a LOU with OWH, which will set forth the details of how the organization is supporting the goals of the observance. Letter of Interest Requirements: Each letter of interest shall contain: (1) Organization name, location, website, and submitter’s contact information; (2) a brief description of the organization’s mission and/or values; and (3) a description of how the organization supports or plans to support the observance(s). Submission of a letter of interest does not guarantee acceptance as a Women’s Health Champion. Authority: 42 U.S.C. 237a; 42 U.S.C. 300u–2(a) and 300u–3; and section 13005 of the 21st Century Cures Act. Dated: August 25, 2022. Dorothy Fink, Deputy Assistant Secretary for Women’s Health, Office of the Assistant Secretary for Health. [FR Doc. 2022–19839 Filed 9–13–22; 8:45 am] BILLING CODE 4150–33–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Listening Session on Intimate Partner Violence Office of the Secretary, HHS. Notice of public meeting. AGENCY: ACTION: The U.S. Department of Health and Human Services Office on Women’s Health (OWH) is announcing a virtual listening session on the impact that COVID–19 has had on intimate partner violence (IPV). The purpose of the listening session is to exchange information about this topic and seek input from stakeholders and subject matter experts on an individual basis. khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 18:31 Sep 13, 2022 Jkt 256001 OWH may use that information to inform our work in this area. Members of the general public are also invited to view the meeting. DATES: The listening session will be held on September 28, 2022, from 10 a.m. to 12:00 p.m. Eastern Time. Procedure for Attendance: Register for the listening session: https:// www.zoomgov.com/meeting/register/ vJItfuGgrDsoGxF_ gSJjxdsDaFplyPZKdVo. Website: You can find more information on https:// www.womenshealth.gov/ ipvlisteningsession. Questions for Discussion: OWH seeks to better understand the role the COVID–19 pandemic may play in the reported rise of IPV. Questions for discussion at the public session may include, but are not limited to: • What are you seeing in terms of the pandemic’s impact on IPV trends? • What effective interventions have you identified to address IPV? • How and when can we best engage organizations around IPV in the future? • What are your organization’s suggestions on including perspectives of underserved communities? • What has worked well in your collaboration with government agencies and offices around IPV? Conversely, what is one key barrier you encountered? • How can we improve trust with the communities you represent, work most closely with, and/or advocate on behalf of? • What is your top priority related to the impact of COVID–19 on IPV? • What should we continue to focus on? • Are there any missed opportunities? • How do you think we can best provide access to information related to COVID–19’s impact on IPV? SUPPLEMENTARY INFORMATION: I. Background: One recent study in the Journal of Interpersonal Violence revealed 64 percent of individuals who experienced IPV since the start of the COVID–19 pandemic reported that violence was a new characteristic of their relationship (Peitzmeier 2021). We invite organizations who work with victims of IPV; Federal, State, local, and tribal public health officials; and law enforcement to provide insights into the current state of IPV and the impact of the COVID–19 pandemic on IPV. Members of the general public are also invited to view the session. Topics for Listening Session: The listening session is an opportunity for the HHS OWH to hear what individual stakeholders and subject matter experts PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 56427 are experiencing with regard to the pandemic’s influence on IPV, what we should consider when providing assistance or programming, how to include the perspectives of underserved communities, and what stakeholders see as the top priorities in addressing IPV. II. Participation: The meeting is free and open to the public. Registration is required. Details on how to register for this listening session can be found at the top of the Notice. Listening Session Availability: A recording of the listening session will be posted to the OWH YouTube channel, and a transcript of the listening session will be posted at https:// www.regulations.gov. References Peitzmeier, Sarah M., Lisa Fedina, Louise Ashwell, et. al. 2021. ‘‘Increases in Intimate Partner Violence During COVID–19: Prevalence and Correlates.’’ Journal of Interpersonal Violence 8862605211052586. doi: 10.1177/ 08862605211052586. Dated: August 24, 2022. Dorothy Fink, Deputy Assistant Secretary for Women’s Health, Office of the Assistant Secretary for Health. [FR Doc. 2022–19850 Filed 9–13–22; 8:45 am] BILLING CODE 4150–33–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the National Vaccine Advisory Committee Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) is hereby giving notice that the National Vaccine Advisory Committee (NVAC) will hold an inperson meeting. The meeting will be open to the public and public comment will be heard during the meeting. DATES: The meeting will be held June 22–23, 2022. The confirmed meeting times and agenda will be posted on the NVAC website at https://www.hhs.gov/ nvpo/nvac/meetings/ as soon as they become available. ADDRESSES: Instructions regarding attending this meeting will be posted online at: https://www.hhs.gov/nvpo/ nvac/meetings/ at least one week prior to the meeting. PreSUMMARY: E:\FR\FM\14SEN1.SGM 14SEN1 56428 Federal Register / Vol. 87, No. 177 / Wednesday, September 14, 2022 / Notices registration is required for those who wish to attend the meeting or participate in public comment. Please register at https://www.hhs.gov/nvpo/nvac/ meetings/. FOR FURTHER INFORMATION CONTACT: Ann Aikin, Acting Designated Federal Officer at the Office of Infectious Disease and HIV/AIDS Policy, U.S. Department of Health and Human Services, Mary E. Switzer Building, Room L618, 330 C Street SW, Washington, DC 20024. Email: nvac@ hhs.gov. Telephone: 202–494–1719. Pursuant to section 2101 of the Public Health Service Act (42 U.S.C. 300aa–1), the Secretary of HHS was mandated to establish the National Vaccine Program to achieve optimal prevention of human infectious diseases through immunization and to achieve optimal prevention against adverse reactions to vaccines. The NVAC was established to provide advice and make recommendations to the Director of the National Vaccine Program on matters related to the Program’s responsibilities. The Assistant Secretary for Health serves as Director of the National Vaccine Program. The NVAC will hear presentations on COVID–19, monkeypox, influena, and polio vaccination, as well as vaccine safety, innovation, and gaps in rural vaccination coverage. Please note that agenda items are subject to change, as priorities dictate. Information on the final meeting agenda will be posted prior to the meeting on the NVAC website: https://www.hhs.gov/nvpo/ nvac/. Members of the public will have the opportunity to provide comment at the NVAC meeting during the public comment period designated on the agenda. Public comments made during the meeting will be limited to three minutes per person to ensure time is allotted for all those wishing to speak. Individuals are also welcome to submit written comments in advance. Written comments should not exceed three pages in length. Individuals submitting comments should email their written comments or their request to provide a comment during the meeting to nvac@ hhs.gov at least five business days prior to the meeting. khammond on DSKJM1Z7X2PROD with NOTICES SUPPLEMENTARY INFORMATION: Dated: 08/22/2022. Ann Aikin, Acting Designated Federal Official, Office of the Assistant Secretary for Health. [FR Doc. 2022–19849 Filed 9–13–22; 8:45 am] BILLING CODE 4150–44–P VerDate Sep<11>2014 18:31 Sep 13, 2022 Jkt 256001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Allergy, Immunology, and Transplantation Research Committee Allergy, Immunology, and Transplantation Research Committee (AITC). Date: October 6–7, 2022. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G51, Rockville, MD 20892 (Virtual Meeting). Contact Person: Thomas F. Conway, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious, National Institutes of Health, NIAID, 5601 Fishers Lane, Room 3G51, Bethesda, MD 20892–9834, 240–669–5075, thomas.conway@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: September 8, 2022. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–19832 Filed 9–13–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Human Genome Research Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Human Genome Research Institute Initial Review Group Genome Research Study Section GNOM–G—CEGS. Date: November 3–4, 2022. Time: 9 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Suite 3100, Bethesda, MD 20817 (Virtual Meeting). Contact Person: Keith McKenney, Ph.D., Scientific Review Officer, National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Suite 3100, Bethesda, MD 20817, 301–594– 4280, mckenneyk@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS.) Dated: September 9, 2022. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–19871 Filed 9–13–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Director, National Institutes of Health; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the NIH Clinical Center Research Hospital Board. The meeting will be held as a virtual meeting and open to the public. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting should notify the Contact Person(s) listed below in advance of the meeting. The meeting can be accessed from the NIH video https://videocast.nih.gov/ and the CCRHB website https:// ccrhb.od.nih.gov/meetings.html. Name of Committee: NIH Clinical Center Research Hospital Board. Date: October 21, 2022. E:\FR\FM\14SEN1.SGM 14SEN1

Agencies

[Federal Register Volume 87, Number 177 (Wednesday, September 14, 2022)]
[Notices]
[Pages 56427-56428]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-19849]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the National Vaccine Advisory Committee

AGENCY: Office of Infectious Disease and HIV/AIDS Policy, Office of the 
Assistant Secretary for Health, Office of the Secretary, Department of 
Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: As stipulated by the Federal Advisory Committee Act, the 
Department of Health and Human Services (HHS) is hereby giving notice 
that the National Vaccine Advisory Committee (NVAC) will hold an in-
person meeting. The meeting will be open to the public and public 
comment will be heard during the meeting.

DATES: The meeting will be held June 22-23, 2022. The confirmed meeting 
times and agenda will be posted on the NVAC website at https://www.hhs.gov/nvpo/nvac/meetings/ as soon as they become 
available.

ADDRESSES: Instructions regarding attending this meeting will be posted 
online at: https://www.hhs.gov/nvpo/nvac/meetings/ at least 
one week prior to the meeting. Pre-

[[Page 56428]]

registration is required for those who wish to attend the meeting or 
participate in public comment. Please register at https://www.hhs.gov/nvpo/nvac/meetings/.

FOR FURTHER INFORMATION CONTACT: Ann Aikin, Acting Designated Federal 
Officer at the Office of Infectious Disease and HIV/AIDS Policy, U.S. 
Department of Health and Human Services, Mary E. Switzer Building, Room 
L618, 330 C Street SW, Washington, DC 20024. Email: [email protected]. 
Telephone: 202-494-1719.

SUPPLEMENTARY INFORMATION: Pursuant to section 2101 of the Public 
Health Service Act (42 U.S.C. 300aa-1), the Secretary of HHS was 
mandated to establish the National Vaccine Program to achieve optimal 
prevention of human infectious diseases through immunization and to 
achieve optimal prevention against adverse reactions to vaccines. The 
NVAC was established to provide advice and make recommendations to the 
Director of the National Vaccine Program on matters related to the 
Program's responsibilities. The Assistant Secretary for Health serves 
as Director of the National Vaccine Program.
    The NVAC will hear presentations on COVID-19, monkeypox, influena, 
and polio vaccination, as well as vaccine safety, innovation, and gaps 
in rural vaccination coverage. Please note that agenda items are 
subject to change, as priorities dictate. Information on the final 
meeting agenda will be posted prior to the meeting on the NVAC website: 
https://www.hhs.gov/nvpo/nvac/.
    Members of the public will have the opportunity to provide comment 
at the NVAC meeting during the public comment period designated on the 
agenda. Public comments made during the meeting will be limited to 
three minutes per person to ensure time is allotted for all those 
wishing to speak. Individuals are also welcome to submit written 
comments in advance. Written comments should not exceed three pages in 
length. Individuals submitting comments should email their written 
comments or their request to provide a comment during the meeting to 
[email protected] at least five business days prior to the meeting.

    Dated: 08/22/2022.
Ann Aikin,
Acting Designated Federal Official, Office of the Assistant Secretary 
for Health.
[FR Doc. 2022-19849 Filed 9-13-22; 8:45 am]
BILLING CODE 4150-44-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.